Lilly presents trial data on a promising Alzheimer’s drug

In the donanemab study, Lilly treated patients with Alzheimer’s as an oncologist can stage and treat cancer, Lilly, chief scientific officer Daniel Skovronksy said in an interview before the presentation. They selected a subset of patients with high levels of amyloid and moderate levels of tau, another abnormal protein associated with brain cell death. The goal was to study patients who were not late with treatment but were affected enough to show benefit if the drug worked, he said.